# Apama Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apama-medical

- Industry: Medical Devices & Equipment
- Headquarters: Campbell, US
- Website: www.apamamedical.com
- Total disclosed funding: $27M
- Latest round: Series C (Nov 17, 2016)
- Investors on record: 6

## About

Apama Medical, Inc. specializes in developing innovative cardiac devices to enhance minimally invasive electrophysiology procedures, focusing on improving patient outcomes and treatment effectiveness.Founded in 2009 and headquartered in Campbell, US, Apama Medical, Inc. designs cardiac devices for electrophysiology. The company was acquired by Boston Scientific Corporation on October 2, 2017, for approximately USD 300 mn, which included USD 175 mn upfront and contingent payments based on regulatory milestones. The acquisition marked a strategic pivot in Boston Scientific's portfolio, enhancing their offerings in electrophysiology.Apama Medical, Inc. develops advanced medical devices tailored for cardiac care, specifically targeting electrophysiology. Their product line is focused on enabling minimally invasive procedures that aim to treat various cardiac conditions, thus improving patient management and outcomes. The company’s technology is designed to assist healthcare providers in performing efficient procedures, ultimately enhancing patient care.Apama Medical, Inc. generates revenue through the sale of its specialized cardiac devices to healthcare institutions, primarily hospitals and surgical centers. The revenue model includes direct sales and partnerships with distributors, ensuring that their innovative products reach a wide array of healthcare providers. This structured approach facilitates predictable revenue streams as they cater to specific needs within the healthcare sector.With the acquisition by Boston Scientific, Apama Medical, Inc. plans to leverage its resources to develop and launch new cardiac devices aimed at enhancing electrophysiological treatments. The company is anticipated to focus on expanding its presence in North America and Europe by 2025, utilizing the recent funding from the acquisition to support product development and market penetration initiatives. The strategic investment will also enable the company to explore additional market opportunities in Asia-Pacific, aligning with the healthcare industry's growing demand for innovative cardiac solutions.

## Funding rounds

- Series C, Nov 17, 2016, $13M — ONSET Ventures, Ascension Ventures, Delos Capital Partners, Incept
- Series B, Jan 13, 2015, $11M — ONSET Ventures, Ascension Ventures, MedVance Institute
- Series A, Sep 16, 2013, $3.2M — Broadview Ventures

## Investors

- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Series A
- ONSET Ventures (https://capitalatlas.ai/funds/onset-ventures) — Series B, Series C
- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Series B, Series C
- MedVance Institute — Series B
- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series C
- Incept (https://capitalatlas.ai/funds/incept) — Series C